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The effects of mycobacteria in prostate cancer have not been fully elucidated. Results of early studies indicated 
that mycobacterial immunotherapy conferred a survival benefit in patients with advanced prostate cancer, and 
recent evidence supports the safety and efficacy of new mycobacterial agents in many malignancies; thus, 
modern, carefully designed, randomized controlled trials of mycobacterial immunotherapy for prostate cancer 
could be warranted. 
Impressive advances in the field of prostate cancer immunotherapy have been made in the past decade. For example, sipuleucel-T was approved by 
the FDA in April 2010 for use in patients with metastatic castration-resistant prostate cancer. However, the clinical results remain modest: overall 
survival is prolonged by only a few months and no benefit is seen in progression-free survival; furthermore, checkpoint inhibition suffers from 
similar limitations1. Thus, the success of immunotherapies in the context of genitourinary malignancies remains confined to the use of BCG for 
non-muscle-invasive bladder carcinomas. Even so, our understanding of molecular immunology has increased substantially in recent years, and 
new ways of expanding the role of immunotherapy are constantly being considered. 
The development of prostate cancer immunotherapies is inherently complex. Finding the optimal scheme for administration and using well-
validated biomarkers or volumetric criteria of response are considerable challenges in clinical trial design. Also, prostatic malignancies have 
biological characteristics widely considered to be unfavourable for immunotherapy, such as a low immune cell density or mutational burden. 
However, high infiltrating immune cell density or mutational burdens do not necessarily correlate with clinical benefit2. Also, the introduction of 
PSA screening has resulted in a large diagnostic migration towards low-risk tumours that need to be addressed but not overtreated. Interestingly, 
patients with low disease burden are less likely to have tumour-induced immune dysfunction and, therefore, could be better suited for 
immunotherapies that generate early antitumour responses. Ideally, such therapies should be safe to administer in patients with low-stage prostate 
cancer, dampen cancer-induced immunosuppression, recruit appropriate populations of effector cells in the tumour microenvironment, induce 
measurable effects in tissues or biological fluids and be easily combined with existing treatments without increasing toxicity risk. 
Some evidence suggests that mycobacterial preparations could fulfil one or more of these criteria. Work on animal and cell line models has 
previously shown that mycobacterial extracts inhibit the proliferation of transformed cells and restore T helper 1 (TH1) cell immunity, while 
recently discovered mycobacterial strains, such as Mycobacterium vaccae and Mycobacterium obuense, are able to stimulate γδ T cells, a critical 
component of antitumour immunity3. Whether these results can be translated to treatment of patients with prostate cancer is currently unknown, 
but some lessons can be learned from the administration of mycobacteria against various malignancies. For example, SRL172 (heat-killed 
M. vaccae) has been administered to patients with metastatic renal cell carcinoma (RCC) after nephrectomy4. No statistically significant differences 
in survival were seen between the SRL172 and the biological therapy (IL-2 or TNF) arm, but the survival of patients receiving chemotherapy was 
worse than that of patients who received other treatments (P < 0.001), suggesting that SRL172 is at least as effective as traditional disease modifiers. 
Another group randomized 419 patients with stage III–IV non-small-cell lung cancer to SRL172 plus chemotherapy versus chemotherapy alone. 
No difference in overall survival was initially found, but re-analysis of the study data (based on the observation that only 53% of patients in the 
combination arm received more than two SRL172 injections) indicated that patients with non-squamous lung adenocarcinoma adhering to the full 
dosing schedule lived on average 357 days (95% CI 293–421) versus only 222 days (95% CI 180–263) in the chemotherapy group5. To date, only a 
few formal trials have investigated the effects of intradermal IMM-101 (heat-killed M. obuense) immunotherapy; the largest was a phase II study 
(NCT01303172) assessing the safety and efficacy of IMM-101 combined with gemcitabine in 110 patients with locally advanced or metastatic 
pancreatic adenocarcinoma6. Overall survival for the intention-to-treat population was 6.7 months for IMM-10 plus gemcitabine versus 
5.6 months for gemcitabine alone (HR 0.68, 95% CI 0.44–1.04, P = 0.074). Differences in overall survival between the two arms were also observed 
in the metastatic disease subgroup (OS 7.0 versus 4.4 months; HR 0.54, 95% CI 0.33–0.87, P = 0.01), whereas injection site reactions were mild to 
moderate. 
With regard to prostate cancer, most studies on mycobacterial immunotherapies were performed before the study of molecular biology or 
monoclonal antibody technology and are, therefore, difficult to interpret. However, in a 1973 trial that aimed to determine the effect of BCG on 
survival and immunological parameters in patients with prostate cancer of all stages, interim reports showed a favourable safety profile of 
intradermal administration. Overall survival differences between the intervention and control arms reached statistical significance (OS for all 
stages: 37.5 versus 21 months, P = 0.02), whereas stage-specific survival differences were larger in lower stage disease7. Although initially all patients 
were treated, stratification and randomization were consistent after 1976, and the results indicated that intradermal BCG is effective, safe and able 
to stimulate the immune system. In a 1998 phase I/II trial, SRL172 was administered in ten patients with hormone-resistant, advanced prostate 
cancer8. The injection only caused mild redness and swelling (5–8 mm) at the administration site in most patients and fever in one, but no other 
major systemic reactions were recorded. PSA reduction was seen in five men, two of whom received SRL172 as their only treatment. The results 
also indicated that men with advanced prostate cancer have a TH2 cytokine profile within their peripheral blood mononuclear cells, which 
predominantly secrete IL-4. Interestingly, SRL172 vaccination was associated with IL-2 production in three of ten men, a cytokine considered to be 
a crucial component of cell-mediated immunity. 
Collectively, these results indicate that mycobacteria are safe, well tolerated and could shift immune responses from TH2 (predominantly 
humoral and associated with cancer progression) to TH1 (predominantly cell-mediated and associated with antitumour responses). Improvements 
in trial design could enable the study of mycobacterial strains that are well tolerated when delivered systemically (such as M. vaccae and 
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M. obuense) and could, therefore, be administered early in the treatment pathway, before prostate cancer-induced or treatment-related immune 
dysfunction is established. Experimental evidence supports the notion that early disease modulation could be effective; for example, the therapeutic 
vaccination of TRAMP mice against specific prostate tumour antigens is more effective in mice with prostatic intraepithelial neoplasia than those 
with already established cancers9. Monitoring tumour responses in early stages is challenging, but recent advances in imaging could enable the 
longitudinal monitoring of low-risk tumours and facilitate repeated sampling of a particular disease focus. Other interventions have been 
previously tested in this manner10 and it could be possible to extend these methodologies in immunotherapy trials. Whether trials like these would 
have any practical value remains to be seen, but in an era in which effective prostate cancer treatments are highly desirable, having a fresh, critical 
look into concepts previously dismissed as, apparently, ineffective could be a way forward. 
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